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Abstract
The pathogenesis of SpA is multifactorial and involves a range of immune cell types and cytokines, many
of which utilize Janus kinase (JAK) pathways for signaling. In this review, we summarize the animal and
pre-clinical data that have demonstrated the effects of JAK blockade on the underlying molecular mech-
anisms of SpA and provide a rationale for JAK inhibition for the treatment of SpA. We also review the
available clinical trial data evaluating JAK inhibitors tofacitinib, baricitinib, peficitinib, filgotinib and upada-
citinib in PsA, AS and related inflammatory diseases, which have demonstrated the efficacy of these
agents across a range of SpA-associated disease manifestations. The available clinical trial data, sup-
ported by pre-clinical animal model studies demonstrate that JAK inhibition is a promising therapeutic
strategy for the treatment of SpA and may offer the potential for improvements in multiple articular and
extra-articular disease manifestations of PsA and AS.
Key words: spondyloarthropathies (including psoriatic arthritis), DMARDs, cytokines and inflammatory medi-
ators, bone, gastrointestinal, ligaments and tendons, skin, synovium
Rheumatology key messages
. Janus kinases mediate cytokine signaling for many immune cell responses underlying the pathogenesis of
spondyloarthritis.
. Janus kinase inhibition offers the potential for improvements in articular and extra-articular spondyloarthritis
disease manifestations.
. Tofacitinib and other Janus kinase inhibitors may provide clinically meaningful benefits for patients with
spondyloarthritis.
Introduction
SpA encompass PsA and AS, and a wider spectrum of
inflammatory diseases. In addition to skeletal involvement
encompassing peripheral arthritis, axial disease, isolated
enthesitis and dactylitis, PsA and AS are associated with a
range of extra-articular manifestations, including uveitis,
psoriasis and IBD [1]. SpA currently has fewer therapeutic
options than RA, and sometimes exhibits heterogeneous
therapeutic responses between skeletal, eye and gut
involvement. Given the complexity of SpA and the need
for new therapeutic options, this review considers the
entire disease spectrum with respect to Janus kinase
(JAK) inhibition and was undertaken after a meeting by a
group of experts active in SpA research.
Unmet treatment need in SpA
Treatment recommendations recognize that appropriate
choice of therapy for SpA depends upon multiple factors
and should be optimized based on the presenting
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symptoms, involvement of other diseases and comorbid-
ities, disease activity and prior therapies. TNF inhibitors
(TNFi) feature in recent treatment recommendations for
PsA in all key domains, including peripheral arthritis,
axial disease, enthesitis, dactylitis, plaque psoriasis and
nail psoriasis [2]. Similarly, TNFi are approved in AS and
have demonstrated efficacy in improving axial and periph-
eral arthritis as well as other articular and entheseal dis-
ease manifestations. While TNFi demonstrate efficacy
across key disease domains, a significant proportion of
patients have inadequate or poor response and others
may not tolerate these therapies [3]. Consequently, treat-
ments with alternative mechanisms of action (MoA) may
be welcomed for patients with SpA.
As our understanding of SpA pathogenesis has
increased, the importance of innate immunity and cytokine
signaling pathways rather than classical adaptive immunity
has fully emerged. This is evidenced through the emergence
of novel agents that target IL-12/23, IL-17 A and IL-23 [4],
which have been developed and have often shown better
efficacy in PsA compared with in RA [5].
JAK inhibitors
JAK inhibitors are an emerging class of therapies that
have demonstrated efficacy for the treatment of inflamma-
tory diseases, in which they have broad effects on cyto-
kine production [6]. There are several excellent recent
papers on the JAK pathway itself, which will not be dis-
cussed further [7, 8]. In this paper, we review and interpret
the available basic and clinical evidence to provide con-
text and rationale for the use of JAK inhibitors for the
treatment of PsA and AS. We discuss why it is that, at
the population level, neither TNF nor IL-17 directly signal
via JAK pathways, and relate this to the efficacy of JAK
inhibition in experimental SpA and emergent clinical data.
Immunopathogenesis of SpA
The aetiology of SpA is complex, with interacting environ-
mental and genetic factors combining to elicit a chronic
inflammatory response involving the innate and adap-
tive immune systems (Fig. 1). At the micro-anatomical
level, there is increasing evidence—especially from
animal models—that the earliest disease manifestations
in arthritis emanate from entheses, with inflammation sub-
sequently involving immediately adjacent tissues, includ-
ing synovioentheseal complexes [9]. Genome-wide
association studies have identified a number of genetic
risk factor variants common to PsA and AS, including
HLA-B27, IL23R, IL1A and IL12B [10]. Several of these
genetic risk factors are also associated with psoriasis
and IBD [11].
A key mechanism in the immunopathogenesis of psor-
iasis is thought to centre on the cluster of differentiation
(CD)8+ T cell response against melanocyte peptides, but
thus far, direct proof in the case of PsA or AS has been
lacking [12]. However, analogous to skin disease, a
population of CD8+ T cells that are enriched for IL-17
production is evident compared with RA [13]. In PsA, the
infiltration of macrophages and activated T cells into
articular locations leads to the production of effector
cytokines, including IL-1b, IL-2, IL-10, IFNg and TNFa,
and further recruitment and proliferation of immune cells
associated with tissue destruction [14]. However, in PsA
and AS, there is strong experimental evidence that
disease localization and the initial inflammation occurs at
entheses and other sites of high mechanical stress,
including the sacroiliac (SI) joints [15].
The IL-23/IL-17 axis is strongly implicated in the patho-
genesis of PsA and AS [14] and in the psoriatic skin pheno-
type [16]. IL-23 contributes to differentiation of innate and
adaptive cognate T cell-expressing lymphocytes which, in
turn, secrete IL-17 A, IL-22 and TNFa [14]. These effector
cytokines are linked to keratinocyte production associated
with skin manifestations of psoriatic disease and to
erosions and new bone formation, although the exact
mechanisms underlying the altered phenotypes in the
skin and joint are not well understood [14].
There is increased interest in the potential role that the
human intestinal microbiome plays in the pathogenesis of
diseases such as PsA and AS [1719]. When the normal
homeostasis that exists between the gut microbiota and
immune cells in the gut lining is disrupted, the ensuing
dysbiosis may contribute to systemic inflammation.
Similar to the pathogenesis of IBD, in SpA the inflamma-
tory response is likely typified by IL-23mediated activa-
tion of innate and adaptive intestinal lymphocytes,
providing further support for therapeutic strategies target-
ing the IL-22 and IL-23/IL-17 axis [20].
JAKSTAT signaling
A large number of cytokines, including many of those
implicated in the pathogenesis of SpA, signal through
JAK pathways (Fig. 2). The JAK family of intracellular pro-
tein tyrosine kinases consists of JAK1, JAK2, JAK3 and
tyrosine kinase 2 (TYK2) [21]. In conjunction with Signal
Transducer and Activator of Transcription (STAT) intracel-
lular transcription factors, JAKs mediate signaling for a
range of extracellular cytokines and growth factors and
ultimately influence a variety of cellular functions [21].
Cytokine binding to receptors at the cell surface activates
JAKs bound to the intracellular domains of these cytokine
receptors via autophosphorylation events. Subsequently,
activated JAKs phosphorylate sites on intracellular do-
mains of cytokine receptors that become docking
sites for STAT molecules from the cell cytoplasm. STAT
molecules are then phosphorylated by the activated JAKs.
Phosphorylated STATs dissociate from the intracellular
domain of the receptor and form dimers that regulate
gene expression and DNA transcription in the cell
nucleus [21].
Different cytokines signal using different pairings of
individual JAKs. The six g-common cytokines (IL-2, IL-4,
IL-7, IL-9, IL-15 and IL-21) signal through the JAK1/JAK3
combination, modulating adaptive immune functions,
including Th cell differentiation and function [21]. Innate
lymphoid cells (ILCs), present in psoriatic skin lesions
and implicated in the pathophysiology of SpA, are also
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strongly dependent upon IL-7 for signaling [22]. IFNg and
IL-12 signaling via JAK1/JAK2 and JAK2/TYK2
combinations, respectively, are critical for Th1 cell
response and ultimately for production of TNFa by macro-
phages [23].
Importantly, given the role of the IL-23/IL-17 axis in SpA
[24], JAKs influence signaling for several key cytokines
involved in this pathway. IL-23, which is produced by
activated dendritic cells, signals using the JAK2/TYK2
combination. As well as direct blockade of IL-23
signaling, an indirect consequence of JAK inhibition is
downstream blockade of IL-17 production [23]. IL-6 is
also involved in ILC type 3 and Th17 cell activation and
functions using the JAK1/JAK2 combination [21]. IL6R
single-nucleotide polymorphisms have been associated
with AS, but thus far, IL-6 blockade has failed in
phase 2 clinical trials [25], and the precise role of IL-6 in
SpA remains to be defined.
Signaling for IL-22, and type I IFNs—which have been
strongly implicated in psoriasis—is mediated by the JAK1/
TYK2 pairing [23]. The cellular and molecular mechanisms
underlying JAK inhibition in psoriasis were elucidated in a
phase 2 randomized trial of tofacitinib, and serve as a
benchmark for MoA studies of JAK inhibitors in SpA
[26]. Analysis of skin lesion biopsies in this trial demon-
strated that tofacitinib attenuated JAKSTAT signaling in
psoriatic keratinocytes (likely mediated by pathogenic
cytokines that use JAK1 to signal, i.e. IL-19, IL-20, IL-22
and IFN) [26]. A further example of the effect of JAK
inhibition on non-immune cell types is provided by studies
of human primary PsA synovial fibroblasts and ex vivo PsA
synovial explants, in which tofacitinib inhibited STAT1 and
STAT3 phosphorylation [27].
Given the range of cytokines that utilize JAKSTATs for
signaling, JAK inhibition offers the potential to modulate
multiple inflammatory pathways implicated in the patho-
genesis of SpA (Fig. 2). Ultimately, activation of these
pathways brings about the proliferation of inflammatory
cells in articular and extra-articular locations, and of cell
types associated with bone loss, joint destruction and
psoriatic skin changes—the hallmarks of SpA [24, 28].
In this context, therefore, therapeutic agents targeting
JAKs could suppress articular as well as extra-articular
symptoms of PsA and AS.
Animal and pre-clinical data evaluating
JAK inhibition in SpA
In the absence of clinical trial data evaluating the MoA for
JAK inhibition in SpA indications, experimental models pro-
vide an opportunity for studying the effects of JAK block-
ade on the underlying molecular mechanisms of the
disease. A number of animal models have been employed
to probe mechanistic aspects of SpA, though none are able
to fully replicate human disease [29]. A common denomin-
ator in these animal models is that the effector mechanisms
are mediated by inflammatory cytokines, including TNF,
IL-17, IL-22, IL-23 and several others. HLA-B27 overex-
pression in rats results in an SpA phenotype featuring col-
itis, arthritis and spondylitis [30]. TNF blockade in this
FIG. 1 Innate and adaptive immune responses in the initiation and perpetuation of SpA
The JAK pathway sits at the crossroads of both key innate and adaptive immune cell populations that are thought to be
important in SpA pathogenesis. The tissue-specific targets of SpA-related disease, including the skeleton, skin and gut,
interact with diverse innate immune cells to maintain tissue homeostasis. Although SpA is immunologically heteroge-
neous, there is strong evidence for adaptive immune responses that could be due to autoantigens or to other antigens
that breech tissue barriers. JAK: Janus kinase; Tc: cytotoxic T cell; Th: T helper; TYK: tyrosine kinase.
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model prevented intestinal and joint disease manifestations
[31], and IL-17 blockade reduced structural damage,
including new bone formation [32]. Deregulated TNF ex-
pression in the TNFARE model induces SpA with
Crohn’s, spine and enthesitis manifestations [33], and b-
glucaninduced SpA in the SKG mouse model results in
a colitis disease phenotype [34]. IL-23induced inflamma-
tion has been studied in a murine model in which innate-like
T cells (most likely gd T cells) triggered inflammation of the
gut, skin, joint and spine [35]. TNFa-induced protein 3 (also
known as A20) negatively regulates inflammation by block-
ing nuclear factor-kB, and entheseal inflammation is a fea-
ture of myeloid-specific A20-deficient mice in which
disease commences in the synovioentheseal complex of
the Achilles tendon [36]. Many of the cytokines driving in-
flammation in these models are under the control of
JAKSTAT signaling. The proof of this principle is provided
by the A20 deficiency model, in which JAK inhibition with
tofacitinib demonstrated significant reductions in enthesitis
and a direct link between STAT1-dependent inflammation
and A20 deficiency [36]. Importantly, joint inflammation in
the A20 model is independent of TNF, providing pre-clinical
suggestions that JAK inhibition may offer value in TNF-re-
sistant SpA [36]. The effect of JAK inhibition has been stu-
died in murine osteoclast-like cells, in which tofacitinib was
found to inhibit bone destruction mediated by TNFa and IL-
FIG. 2 JAK inhibition of cytokine pathways involved in the pathogenesis of SpA
Cytokine signaling and production at the enthesis: signaling for a number of key cytokine pathways implicated in the
pathogenesis of SpA is blocked through direct inhibition of JAKs, including IFNg, IL-7, IL-12, IL-15, IL-22 and IL-23. Other
important cytokines, such as TNFa, IL-1 and IL-17, signal independently of JAKs, but their expression is regulated by
JAK-dependent cytokines and, therefore, may be blocked indirectly via JAK inhibition. These cytokines influence cellular
function for a broad range of innate and adaptive cell types, including many of those shown in Fig.1. JAK, Janus kinase;
TYK, tyrosine kinase.
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6 [37]. Pre-clinical data have also suggested a link between
JAKSTAT pathways and osteoblast differentiation, with
JAKSTAT signaling implicated in alkaline phosphatase
regulation [38].
Clinical data evaluating JAK inhibitors
Several JAK inhibitors with various reported selectivity
are being investigated for use in autoimmune diseases.
To date, the only JAK inhibitor to have been investigated
in SpA clinical trials is the oral JAK inhibitor tofacitinib.
In cellular assays, tofacitinib demonstrated preferential
inhibition of JAK1 and JAK3, with 5- to 100-fold selectivity
over JAK2 [39]. Its pharmacokinetics are characterized
by rapid absorption (1 h to peak concentration) and elim-
ination (half-life of 3.2 h) [40], and its pharmacodynamic
effects are generally reversible following 14 days of
treatment discontinuation [41].
Clinical trials of tofacitinib have demonstrated efficacy in
reducing the signs and symptoms of PsA. Two phase 3,
randomized controlled trials evaluated tofacitinib 5 mg
twice daily (BID) and 10 mg BID in patients with active PsA
and IR to conventional synthetic DMARDs (csDMARDs) [42]
or TNFi [43]. In OPAL Broaden (NCT01877668), significant
improvements vs placebo in ACR20 response rates (20%
improvement in ACR core set measures) and improvements
from baseline in HAQ-Disability Index (HAQ-DI) scores were
observed with tofacitinib 5 and 10 mg BID at month 3 and
maintained (relative to baseline) to month 12. Improvements
were also seen in enthesitis, dactylitis and skin psoriasis.
In the 6-month trial in TNFi-IR patients (OPAL Beyond
[NCT01882439]), significant improvements vs placebo in
ACR20 response rates and HAQ-DI scores were observed
at month 3 with tofacitinib 5 and 10 mg BID and were
maintained (relative to baseline) to month 6. Enthesitis,
dactylitis and skin psoriasis were also improved. Both
doses showed generally similar clinical efficacy, though
tofacitinib 10 mg BID demonstrated greater efficacy vs
placebo in skin psoriasis compared with 5 mg BID [43].
In a 16-week (12-week treatment, 4-week washout),
phase 2, dose-ranging trial (NCT01786668) in TNFi-naı¨ve
patients with active AS and IR or intolerance to NSAIDs
[44], the ASAS20 response rate was significantly higher vs
placebo with tofacitinib 5 mg BID. Both tofacitinib 5 and
10 mg BID improved objective measures of disease,
including Spondyloarthritis Research Consortium of
Canada MRI scores of SI and spine joints at week 12
[44]. In this study, greater response to tofacitinib was cor-
related with the magnitude of the CRP elevation and the
degree of spinal MRI positivity (Spondyloarthritis
Research Consortium of Canada SI joint cut-off 52) at
baseline. This study demonstrated that JAK inhibitors
may be effective treatment options for axial disease, but
their efficacy has not been fully established and further
studies are required in order to assess their efficacy
over longer follow-up periods.
As outlined previously, IBD (ulcerative colitis [UC] and
Crohn’s disease) and SpA share a number of genetic and
immunopathogenic aspects, with the role of the gut
microbiota implicated in their pathophysiology [45].
Cytokines implicated in the pathogenesis of IBD that
signal using JAKs include IL-2, IL-7, IL-15 and IL-21,
which utilize the JAK1/JAK3 pairing, IFNg (JAK1/JAK2),
IL-22 (JAK1/TYK2) and IL-12 and IL-23 (JAK2/TYK2)
[46]. Randomized controlled trials of tofacitinib demon-
strated a significant effect of treatment for UC [47] but
only modest efficacy for Crohn’s disease [48]. The JAK1
inhibitor filgotinib is also being investigated for Crohn’s
disease and has shown efficacy in inducing clinical remis-
sion in a phase 2 study [49]. With respect to the disparate
efficacy observed with tofacitinib in UC and Crohn’s dis-
eases, there is a consensus that, at the population level,
there is a greater role for adaptive immunity in UC com-
pared with Crohn’s disease [50]. The recently reported
efficacy of tofacitinib in phase 3 UC studies [47] was sub-
stantially greater than that reported in phase 2 studies of
tofacitinib for Crohn’s disease [48]. Given that a greater
role for innate immunity is ascribed to Crohn’s disease
and a greater role for adaptive immunity in UC, these
findings might suggest a greater magnitude of effect of
JAK inhibitors on the adaptive arm of immunity implicated
in the pathogenesis of SpA (as set out in Figs 1 and 2).
In patients with moderate to severe plaque psoriasis,
phase 2 and 3 studies have demonstrated the efficacy
of oral tofacitinib [26, 5153], and a topical formulation
has been assessed for psoriasis [54] and atopic dermatitis
[55]. The MoA of tofacitinib for psoriasis was evaluated in
a phase 2 randomized trial [26]. Marked reduction of cel-
lular immune infiltrates in skin lesions was observed—with
the earliest changes observed in CD11c+ dendritic
cells—as well as a reduction in IL-23/IL-17 axis cytokines
that followed the cellular reductions. These cellular reduc-
tions may be mediated by changes in signaling of
cytokines such as IL-7 (which generally promotes survival
of immune cells) and IL-2. Observed reduction in IL-17
was likely due to an indirect effect of tofacitinib through
modulation of other cytokines that support growth and
survival of the immune cell infiltrates in skin lesions.
As the only study to evaluate tofacitinib MoA in human
disease, results from this study provide important infor-
mation regarding immune cell signaling pathways that
may be generalizable to SpA.
In atopic dermatitis, inhibition of IL-4 via JAK1/JAK3
blockade is thought to modulate Th2-mediated inflamma-
tion in the disease. In addition, improvements in pruritus
noted in the atopic dermatitis trial were linked to inhibition
of IL-31 signaling achieved via JAK1/JAK2 blockade [55].
The oral JAK1/JAK2 inhibitor baricitinib is also being
investigated for psoriasis, and demonstrated a significant
treatment effect in patients with moderate to severe
psoriasis in a 12-week phase 2b dose-ranging trial [56].
Cytokines and activation of Th1 and Th17 cells are also
involved in the pathogenesis of dry eye disease, in which
topical tofacitinib has demonstrated efficacy in improving
signs and symptoms of the disease in a phase 1/2 study
[57]. Although the IL-23/IL-17 pathway is implicated in
the pathogenesis of uveitis, and JAK inhibition thus rep-
resents a promising approach for its treatment, clinical
trials evaluating the efficacy of JAK inhibitors in uveitis
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have not been conducted [58]. In general, there is a sense
that antiIL-17 therapies may be more effective for the
treatment of skin symptoms, whereas TNFi may be
more effective against joint manifestations, depending
on the dose.
In common with SpA, the inflammatory response in RA
is mediated by a range of effector cytokines, a number of
which signal using JAKs, including IL-6, IL-7, IL-10, IL-12,
IL-15, IL-21, IL-23, IFNa and IFNb [41]. The efficacy of
tofacitinib either as monotherapy, or in combination with
csDMARDs, for the treatment of RA has been established
in a variety of patient populations (including DMARD-IR
and TNFi-IR patients) in randomized controlled phase 3
trials and in open-label long-term extension studies
[5965]. Baricitinib has demonstrated clinical efficacy in
a phase 3 randomized controlled trial of patients with
RA refractory to treatment with csDMARDs and biologic
DMARDs (bDMARDs) [66], and is approved in Europe for
the treatment of patients with moderately to severely
active RA. A selective inhibitor of JAK1, upadacitinib
(ABT-494), has demonstrated efficacy in TNFi-IR patients
with RA [67]. Pharmacokinetic/pharmacodynamic ana-
lyses of filgotinib have been conducted and dose-ranging
studies in RA are planned [68]. The JAK1/JAK3 inhibitor
peficitinib demonstrated efficacy vs placebo in patients
with RA when dosed at 50 mg in combination with MTX,
but did not otherwise show a dose-dependent effect over
12 weeks [69].
The efficacy of JAK inhibitors with varying potencies
against the JAK family of tyrosine kinases demonstrated
across the range of inflammatory diseases described
above is likely due to a pan-JAK inhibitory effect, whereby
each of the JAK protein kinases is inhibited to some
degree at the clinical dose. Beyond the direct effects of
tofacitinib and other JAK inhibitors on cytokine signaling,
there is a downstream effect on biologic processes—that
is, inhibition of Th1, Th2 and Th17 functions through
JAK1/JAK3 inhibition of the g-common cytokines—that
contributes to the efficacy of JAK inhibitors. In addition,
cells expressing the IL-7 and IL-15 receptors, including
ILCs, could also be affected via the same pathway
[22, 70]. The clinical efficacy of tofacitinib observed in
SpA indications correlates with the immunomodulatory
effects of tofacitinib characterized in other diseases, but
more data are required to better understand the specific
underlying mechanisms in PsA and AS that are affected
by JAK inhibitors.
Agents that inhibit TYK2 may be advantageous for the
treatment of peripheral arthritis in SpA due to the promin-
ent role of IL-23 signaling (as suggested by genetic
studies), particularly since SpA family diseases are
linked to IL-23 pathway single nucleotide polymorphisms.
Thus, an inhibitor with JAK1/TYK2 specificity may be
expected to deliver greater efficacy than JAK1/JAK3 in-
hibition with tofacitinib or JAK1-selective inhibitors,
through targeting the IL-23 genetic signature (through
TYK2 inhibition) in addition to type I IFN (through JAK1
inhibition). Although JAK2-selective inhibition could inhibit
IL-23 signaling in a similar fashion to a TYK2-selective
agent, it would also inhibit signaling of other hematopoie-
tic factors, such as erythropoietin and thrombopoietin,
potentially leading to undesirable side effects such as
anemia and thrombocytopenia. Though more studies are
required in different disease populations to establish how
JAK inhibitors with different putative JAK selectivity may
be differentiated from one another in the clinic, available
data evaluating cytokine inhibition profiles of different JAK
inhibitor agents currently suggest limited differentiation
between agents at clinically relevant doses [71]. Given
the immunological heterogeneity in the SpAs, and given
that some drugs, including TNF fusion proteins and
antiIL-17 therapies, do not work in IBD and uveitis, the
inhibition of multiple cytokines may auger well for JAK
inhibition across the full spectrum of SpA disease mani-
festations, and there is a strong potential for JAK inhibition
strategies that target the SpA spectrum of disease.
Owing to the pleiotropic nature of JAKSTAT signaling,
including its role in hematopoiesis and host defence,
monitoring the safety profile of JAK inhibitors is an import-
ant aspect of clinical studies evaluating their use. Data
from the tofacitinib RA clinical trials, which include up to
96 months of observation, currently provide perhaps the
best indication of the long-term safety of JAK inhibitors
[72]. In this patient population, incidence rates for adverse
events of special interest (including serious infections,
cardiovascular events, malignancies and mortality) have
not increased with longer tofacitinib exposure. Changes
in laboratory parameters observed with tofacitinib treat-
ment (including decreases in lymphocyte, neutrophil and
platelet counts, and increases in low- and high-density
lipoprotein cholesterol and in serum creatinine) were gen-
erally stable with long-term therapy and reversible with
treatment discontinuation or medical management
(e.g. use of lipid-lowering agents) [72]. The safety profile
of tofacitinib in patients with AS [44], PsA [42, 43], psor-
iasis [5154], atopic dermatitis [55] and IBD [47, 48] has
been generally consistent with that observed in RA, with
no new or unexpected safety findings. However, exposure
and sample size in these patient populations are not as
large as those for RA.
In general, reported safety events for other JAK inhibi-
tors have been consistent with those reported with tofa-
citinib, with infections and small changes in clinical
laboratory parameters a feature of trials evaluating barici-
tinib, upadacitinib and filgotinib [49, 56, 66, 67]. Again,
sample size and drug exposure were relatively low in
these trials, and continued evaluation of the safety profiles
of the different JAK inhibitors in different patient popula-
tions is required.
Conclusions
The SpAs include several chronic inflammatory autoim-
mune conditions with a multifactorial pathogenesis invol-
ving a range of immune cell types and cytokine signaling
pathways. Therapeutic disease management for PsA and
AS is complicated by the variety of musculoskeletal and
extra-articular manifestations with which the diseases
may present. While bDMARDs, including TNFi, IL-12p40
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and IL-17 inhibitors, have demonstrated efficacy in treat-
ing the spectrum of clinical manifestations of SpA, add-
itional agents with novel MoAs could provide useful
alternatives for patients who do not respond or lose initial
response to therapy with bDMARDs across many SpA
manifestations, including those in the gut, skin and joint.
JAKSTAT pathways mediate cytokine signaling for
many innate and adaptive immune responses underlying
the pathogenesis of SpA as well as other associated
inflammatory diseases. Consequently, JAK inhibition is a
promising therapeutic strategy for the treatment of SpA as
it offers the potential for improvements in multiple mani-
festations of PsA and AS.
A number of JAK inhibitors—including tofacitinib, bar-
icitinib, peficitinib, filgotinib and upadacitinib—have
demonstrated efficacy in other autoimmune conditions
of relevance. To date, tofacitinib is the only JAK inhibitor
that has been investigated in PsA and AS clinical trials and
was recently approved for the treatment of PsA by the US
Food and Drug Administration. Studies evaluating other
agents within this MoA class are required in order to
confirm JAK inhibition as an additional treatment option
and to expand upon the available mechanistic information
regarding their use in SpA. Thus far, the efficacy of JAK
inhibitors demonstrated across a variety of SpA-asso-
ciated disease manifestations indicates that they may be
an important new oral therapy option for SpA. As further
research is conducted and additional JAK inhibitors are
evaluated in SpA, tofacitinib and other emerging JAK
inhibitors may add to the available treatment options
and provide clinically meaningful benefits for patients
with SpA.
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